THE RELEVANCE OF THE USE AND RESEARCH OF DRUGS THAT HAVE A POSITIVE EFFECT ON METABOLISM
Article Sidebar
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Main Article Content
Аннотация:
Generally speaking, drugs that affect an organism's metabolism are those that are broken down by the body's metabolic pathways, which frequently involve liver enzymes such as those in the cytochrome P450 family. These medications' duration of action and excretion may be impacted by a variety of metabolic processes, including oxidation, reduction, hydrolysis, and conjugation. Another important factor is the gut microbiota, where bacteria either directly metabolize medications or have an impact on human metabolic processes. The majority of medications are chemically changed by different body systems to produce molecules that are easier for the body to eliminate. These chemical changes, referred to as biotransformations, mostly take place in the liver. Planning customized pharmacological interventions for patients requires an understanding of the molecular changes that medicines go through during metabolism. This exercise goes on polypharmacy, biotransformations, and drug metabolism.
Article Details
Как цитировать:
Библиографические ссылки:
Susa ST, Hussain A, Preuss CV. Drug Metabolism. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK442023/
Zhang Z, Tang W. Drug metabolism in drug discovery and development. Acta Pharm Sin B. 2018 Sep;8(5):721-732. doi: 10.1016/j.apsb.2018.04.003.
Open Resources for Nursing (Open RN); Ernstmeyer K, Christman E, editors. Nursing Pharmacology [Internet]. 2nd edition. Eau Claire (WI): Chippewa Valley Technical College; 2023. Chapter 1 Pharmacokinetics & Pharmacodynamics. Available from: https://www.ncbi.nlm.nih.gov/books/NBK595006/
Liu, H., Wang, S., Wang, J. et al. Energy metabolism in health and diseases. Sig Transduct Target Ther 10, 69 (2025). https://doi.org/10.1038/s41392-025-02141-x
Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. International Journal of Molecular Sciences. 2021; 22(23):12808. https://doi.org/10.3390/ijms222312808
Patel, R.; Barker, J.; ElShaer, A. Pharmaceutical excipients and drug metabolism: A mini-review. Int. J. Mol. Sci. 2020, 21, 8224.
Tao, G.; Huang, J.; Moorthy, B.; Wang, C.; Hu, M.; Gao, S.; Ghose, R. Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 2020, 16, 1109–1124.
Coelho, M.M.; Fernandes, C.; Remião, F.; Tiritan, M.E. Enantioselectivity in drug pharmacokinetics and toxicity: Pharmacological relevance and analytical methods. Molecules 2021, 26, 3113.
Rendic, S.P. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects. Arch. Toxicol. 2021, 95, 1535–1546.
Krkoška, M.; Svobodová, J.; Kabátková, M.; Zapletal, O.; Hyršlová Vaculová, A.; Nekvindová, J.; Vondráček, J. Deregulation of signaling pathways controlling cell survival and proliferation in cancer cells alters induction of cytochrome P450 family 1 enzymes. Toxicology 2021, 461, 152897.
Wang, Y.; He, X.; Li, C.; Ma, Y.; Xue, W.; Hu, B.; Wang, J.; Zhang, T.; Zhang, F. Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification. Eur. J. Med. Chem. 2020, 193, 112235.
Brown, S.A.; Pereira, N. Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine. J. Pers. Med. 2018, 8, 8.
Navarro-Mabarak, C.; Camacho-Carranza, R.; Espinosa-Aguirre, J.J. Cytochrome P450 in the central nervous system as a therapeutic target in neurodegenerative diseases. Drug Metab. Rev. 2018, 50, 95–108.
Sneha, S.; Baker, S.C.; Green, A.; Storr, S.; Aiyappa, R.; Martin, S.; Pors, K. Intratumoural cytochrome P450 expression in breast cancer: Impact on standard of care treatment and new efforts to develop tumour-selective therapies. Biomedicines 2021, 9, 290.
Fritsche K, Ziková-Kloas A, Marx-Stoelting P, Braeuning A. Metabolism-Disrupting Chemicals Affecting the Liver: Screening, Testing, and Molecular Pathway Identification. International Journal of Molecular Sciences. 2023; 24(3):2686. https://doi.org/10.3390/ijms24032686
Heindel, J.J.; Blumberg, B.; Cave, M.; Machtinger, R.; Mantovani, A.; Mendez, M.A.; Nadal, A.; Palanza, P.; Panzica, G.; Sargis, R.; et al. Metabolism disrupting chemicals and metabolic disorders. Reprod. Toxicol. 2017, 68, 3–33.
Alves-Bezerra, M.; Cohen, D.E. Triglyceride Metabolism in the Liver. Compr. Physiol. 2017, 8, 1–22.
Hamoud, A.R.; Weaver, L.; Stec, D.E.; Hinds, T.D., Jr. Bilirubin in the Liver-Gut Signaling Axis. Trends Endocrinol. Metab. 2018, 29, 140–150.
Javed, K.; Fairweather, S.J. Amino acid transporters in the regulation of insulin secretion and signalling. Biochem. Soc. Trans. 2019, 47, 571–590.
Kersten, S.; Stienstra, R. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. Biochimie 2017, 136, 75–84.
Wolf Greenstein, A.; Majumdar, N.; Yang, P.; Subbaiah, P.V.; Kineman, R.D.; Cordoba-Chacon, J. Hepatocyte-specific, PPARgamma-regulated mechanisms to promote steatosis in adult mice. J. Endocrinol. 2017, 232, 107–121.
Mutemberezi, V.; Guillemot-Legris, O.; Muccioli, G.G. Oxysterols: From cholesterol metabolites to key mediators. Prog. Lipid Res. 2016, 64, 152–169.
Tanianskii, D.A.; Jarzebska, N.; Birkenfeld, A.L.; O’Sullivan, J.F.; Rodionov, R.N. Beta-Aminoisobutyric Acid as a Novel Regulator of Carbohydrate and Lipid Metabolism. Nutrients 2019, 11, 524.
Caudle, K.E.; Sangkuhl, K.; Whirl-Carrillo, M.; Swen, J.J.; Haidar, C.E.; Klein, T.E.; Gammal, R.S.; Relling, M.V.; Scott, S.A.; Hertz, D.L.; et al. Standardizing CYP2D6 genotype to phenotype translation: Consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group. Clin. Transl. Sci. 2020, 13, 116–124.